180 related articles for article (PubMed ID: 10597772)
1. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).
Savès M; Vandentorren S; Daucourt V; Marimoutou C; Dupon M; Couzigou P; Bernard N; Mercié P; Dabis F
AIDS; 1999 Dec; 13(17):F115-21. PubMed ID: 10597772
[TBL] [Abstract][Full Text] [Related]
2. Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Morlat P; Marimoutou C; Dequae-Merchadou L; Pellegrin I; Mercié P; Neau D; Beylot J; Dabis F
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):255-60. PubMed ID: 10839661
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
[TBL] [Abstract][Full Text] [Related]
4. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).
Thiébaut R; Dabis F; Malvy D; Jacqmin-Gadda H; Mercié P; ValentinVD
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):261-5. PubMed ID: 10839662
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
[TBL] [Abstract][Full Text] [Related]
6. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
Chêne G; Binquet C; Moreau JF; Neau D; Pellegrin I; Malvy D; Ceccaldi J; Lacoste D; Dabis F
AIDS; 1998 Dec; 12(17):2313-20. PubMed ID: 9863874
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99.
Thiébaut R; Dequae-Merchadou L; Ekouevi DK; Mercié P; Malvy D; Neau D; Dabis F;
HIV Med; 2001 Apr; 2(2):84-8. PubMed ID: 11737383
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
10. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
11. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Spira R; Marimoutou C; Binquet C; Lacoste D; Dabis F
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):358-64. PubMed ID: 9704941
[TBL] [Abstract][Full Text] [Related]
12. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
[TBL] [Abstract][Full Text] [Related]
13. Acute liver enzyme elevations in HIV-1-infected patients.
Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
[TBL] [Abstract][Full Text] [Related]
14. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
15. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
Sulkowski MS; Thomas DL; Chaisson RE; Moore RD
JAMA; 2000 Jan; 283(1):74-80. PubMed ID: 10632283
[TBL] [Abstract][Full Text] [Related]
17. Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda.
Weidle PJ; Moore D; Mermin J; Buchacz K; Were W; Downing R; Kigozi A; Ndazima V; Peters P; Brooks JT
AIDS Patient Care STDS; 2008 Oct; 22(10):787-95. PubMed ID: 18778241
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?
Rancinan C; Neau D; Savès M; Lawson-Ayayi S; Bonnet F; Mercié P; Dupon M; Couzigou P; Dabis F; Chêne G;
AIDS; 2002 Jul; 16(10):1357-62. PubMed ID: 12131212
[TBL] [Abstract][Full Text] [Related]
20. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
